Szefler SJ, Jerschow E, Yoo B, et al. - This post hoc analysis was conducted to estimate response to omalizumab in moderate-to-severe asthma patients of Black and White race in North America. From placebo-controlled (EXTRA)/single-armed (PROSPERO) omalizumab studies, data were obtained. Study sample consisted of 631 White/176 Black patients from EXTRA and 567 White/130 Black patients from PROSPERO. Placebo-corrected alteration in FEV ₁ and Asthma Quality of Life Questionnaire (AQLQ) was estimated by racial group, using an analysis of covariance model. Findings revealed that omalizumab conferred similar improvements in exacerbations, FEV ₁ , and AQLQ between Black and White patients suffering from moderate-to-severe asthma.